Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Prof Maria Ribal discusses how effective dissemination is key to PIONEER’s long-term success

Prof Maria Ribal - Chairperson, EAU Guidelines Dissemination Committee
Prof Maria Ribal discusses how effective dissemination is key to PIONEER’s long-term success ( Prof Maria Ribal - Chairperson, EAU Guidelines Dissemination Committee )
13 May 2019

Louise Fullwood explains the legal and ethical issues around data privacy within PIONEER

Louise Fullwood - Legal Director, Pinsent Masons
Louise Fullwood explains the legal and ethical issues around data privacy within PIONEER ( Louise Fullwood - Legal Director, Pinsent Masons )
13 May 2019

Prof James N’Dow, Academic lead for PIONEER, reflects on the first twelve months of the project

Prof James N’Dow - Chairperson, European Association of Urology Guidelines Office
Prof James N’Dow, Academic lead for PIONEER, reflects on the first twelve months of the project ( Prof James N’Dow - Chairperson, European Association of Urology Guidelines Office )
13 May 2019

Denis Horgan explains the importance of actively engaging policy makers in PIONEER

Denis Horgan - Executive Director, European Alliance for Personalised Medicine
Denis Horgan explains the importance of actively engaging policy makers in PIONEER ( Denis Horgan - Executive Director, European Alliance for Personalised Medicine )
13 May 2019

Dr Billy Franks explains the importance of data analysis plans for PIONEER’s research questions

Dr Billy Franks - Astellas Pharma B.V.
Dr Billy Franks explains the importance of data analysis plans for PIONEER’s research questions ( Dr Billy Franks - Astellas Pharma B.V. )
13 May 2019

Prof Anders Bjartell discusses the data sources and access of the PIONEER data models

Prof Anders Bjartell - Skåne University Hospital, Malmö, Lund University, Sweden
Prof Anders Bjartell discusses the data sources and access of the PIONEER data models ( Prof Anders Bjartell - Skåne University Hospital, Malmö, Lund University, Sweden )
13 May 2019

Dr Alex Asiimwe, EFPIA lead for PIONEER, discusses the unique public-private aspects of BD4BO

Dr Alex Asiimwe - Director, BAYER AG, Medical affairs, Epidemiology
Dr Alex Asiimwe, EFPIA lead for PIONEER, discusses the unique public-private aspects of BD4BO ( Dr Alex Asiimwe - Director, BAYER AG, Medical affairs, Epidemiology )
13 May 2019

Second-line and beyond in mCRC: Optimising the benefit and reducing the risk

Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk ( Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA )
9 May 2019

Controversies in the management of prostate cancer

Prof Mach Roach III - University of California, San Francisco, USA
Controversies in the management of prostate cancer ( Prof Mach Roach III - University of California, San Francisco, USA )
9 May 2019

Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months

Prof John Marshall - Georgetown University Hospital, Washington D.C., USA
Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months ( Prof John Marshall - Georgetown University Hospital, Washington D.C., USA )
9 May 2019

Rectal cancers: Positioning of watchful waiting and minimally invasive procedures

Prof Henk Wegstapel - Canterbury Christ Church University, Canterbury, UK
Rectal cancers: Positioning of watchful waiting and minimally invasive procedures ( Prof Henk Wegstapel - Canterbury Christ Church University, Canterbury, UK )
9 May 2019

Using genetic testing to tailor chemotherapy

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Using genetic testing to tailor chemotherapy ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
9 May 2019